Showing 491-500 of 1560 results for "".
How Does the Skin Repair Itself? A Study on Skin Regeneration
https://reachmd.com/programs/dermconsult/how-does-the-skin-repair-itself-a-study-on-skin-regeneration/12638/What’s the latest research on skin regeneration, and how might it influence the regeneration of other tissues and organs?Why Do Males Have More Liver Cancer Than Females?
https://reachmd.com/programs/clinicians-roundtable/why-do-males-have-more-liver-cancer-than-females/3104/Arlin Rogers, PhD, chief of comparative pathology at the Massachusetts Institute of Technology, details a new genome study which is helping to explain why men are saddled with liver cancer more often than their gender counterparts. Dr. Rogers aims to raise awareness for the influence of hepatitis BPromising New Biomarker to Predict Colorectal Cancer Recurrence
https://reachmd.com/programs/focus-on-cancer/promising-new-biomarker-to-predict-colorectal-cancer-recurrence/4324/How is the biomarker guanylyl cyclase 2C helping to predict colorectal cancer recurrence rates? Host Dr. Lee Freedman welcomes Dr. Scott Waldman, professor in the departments of medicine and biochemistry at Thomas Jefferson University, to discuss how this biomarker found in regional lymph nodes canRethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
https://reachmd.com/programs/living-rheum/sle-treatment-approvals-novel-targets/39846/Systemic lupus erythematosus (SLE) treatment is undergoing a transformative shift from broad immunosuppression to targeted, precision-based approaches. Dr. Marc Scherlinger joins Dr. Steve Jackson to provide a timely update on recent breakthroughs, including monoclonal antibodies, JAK and BTK inhibiEvaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
https://reachmd.com/programs/spotlight-subcutaneous--cancer-immunotherapy/evaluating-alemtuzumab-in-adult-all-insights-from-a-phase-12-clinical-trial/32993/Alemtuzumab may have potential as an adult acute lymphoblastic leukemia treatment. Dive deeper into its safety, efficacy, and implications for care.Amesh Adalja, Infectious Disease Expert, Answers Your Latest COVID-19 Questions
https://reachmd.com/programs/public-health-call/amesh-adalja-infectious-disease-expert-answers-your-latest-covid-19-questions/11429/Is there any truth behind using hydroxychloroquine as a treatment? An infectious disease expert answers this and other FAQs.Pediatric Diabetes Research
https://reachmd.com/programs/diabetes-discourse/pediatric-diabetes-research/6147/Diabetes research is the cornerstone for new opportunities in the treatment of patients living with diabetes. How will the newly formed Pediatric Diabetes Research Center serve this goal? Join guest host, certified diabetes educator Janice Baker and Dr. Alberto Hayek, professor of pediatrics and co-Examining the Role of Toxic Tau Proteins in Alzheimer's Disease
https://reachmd.com/programs/neurofrontiers/examining-the-role-of-toxic-tau-proteins-in-alzheimers-disease/17827/What’s the role of toxic tau proteins in Alzheimer's disease? Tune in to find out.Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
https://reachmd.com/programs/project-oncology/reevaluating-race-in-spirometry-advancing-equity-in-pulmonary-risk-assessment/39035/Race-based spirometry adjustments have long influenced pulmonary risk assessments, often underestimating disease severity in Black patients. Hear from Dr. Ajay Sheshadri as he examines the historical misuse of race in lung function testing, explores race-neutral modeling in surgical risk prediction,Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
https://reachmd.com/programs/project-oncology/advancing-multiple-myeloma-treatment-the-role-of-immunotherapy-and-personalized-care/30051/Advancements in multiple myeloma treatment have significantly improved patient outcomes. Explore the latest therapies and their impact on personalized care.